Last edition
News about "Andrew King"
Jade Biosciences Doses First Patient in Phase 2 Trial of JADE101 for IgA Nephropathy
Jade Biosciences announces first patient dosing in the phase 2 JUNIPER trial evaluating JADE101 for IgA nephropathy, with interim clinical data expected in 2027.
Andrew King | 26/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members